Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Tucidinostat. |
| Vorinostat | The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Tucidinostat is combined with Vorinostat. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Dofetilide. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Citalopram. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Anagrelide. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Disopyramide. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Clemastine. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Ibutilide. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Valproic acid. |
| Terfenadine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Terfenadine. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Grepafloxacin. |
| Quinine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Quinine. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Sotalol. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Erlotinib. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Toremifene. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Cisapride. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Imatinib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Astemizole. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Thioridazine. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Trovafloxacin. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Mifepristone. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Tucidinostat is combined with Cocaine. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Quinidine. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Procainamide. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Pimozide. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Amiodarone. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Arsenic trioxide. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Escitalopram. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Domperidone. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Sparfloxacin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Halofantrine. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Bepridil. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Paliperidone. |
| Lithium cation | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Lithium cation. |
| Temafloxacin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Temafloxacin. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Zuclopenthixol. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Tetrabenazine. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Dronedarone. |
| Nilotinib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Nilotinib. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Iloperidone. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Vandetanib. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Romidepsin. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Asenapine. |
| Artemether | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Artemether. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Lumefantrine. |
| Vemurafenib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Vemurafenib. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Eliglustat. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Tucidinostat. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Glasdegib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Deutetrabenazine. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Macimorelin. |
| Terodiline | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Terodiline. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tucidinostat. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tucidinostat. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Tucidinostat. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Tucidinostat. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tucidinostat. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Tucidinostat. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Tucidinostat. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Tucidinostat. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Tucidinostat. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Tucidinostat. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Clozapine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Tucidinostat. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Tucidinostat. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Tucidinostat. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Tucidinostat. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Tucidinostat. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Tucidinostat. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Tucidinostat. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Tucidinostat. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Tucidinostat. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Tucidinostat. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Tucidinostat. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Tucidinostat. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Tucidinostat. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Tucidinostat. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Tucidinostat. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Tucidinostat. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Tucidinostat. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Tucidinostat. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Tucidinostat. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Tucidinostat. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Tucidinostat. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Tucidinostat. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Tucidinostat. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Tucidinostat. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Tucidinostat. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Tucidinostat. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Tucidinostat. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Tucidinostat. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Tucidinostat. |
| Telithromycin | The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Tucidinostat. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Tucidinostat. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Tucidinostat. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Primaquine is combined with Tucidinostat. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tucidinostat. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Tucidinostat. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Tucidinostat. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Tucidinostat. |